Annual Report 2003 Aventis - Sanofi

In the United States, the world’s largest pharmaceutical
market, sales increased 11.1 % on an activity
basis, driven by the ongoing strong performance
of strategic brands and human vaccines, which accounted
for 86.9 % of total sales in the country in
2003 compared to 83.7 % in 2002. Taxotere, Lantus
and Lovenox / Clexane reported double-digit sales increases,
helping to offset essentially fl at sales of
Allegra / Telfast.
An additional growth driver was the strong performance
of U.S.-based Dermik, now conducting the
North American prescription dermatology business
of Aventis Dermatology. Dermik achieved sales of
>> 52